Total Payments
$1.1M
2024 Payments
$152,566
Companies
48
Transactions
1,713
Medicare Patients
460
Medicare Billing
$66,937
Payment Breakdown by Category
Other$750,176 (66.4%)
Consulting$189,218 (16.7%)
Travel$137,355 (12.2%)
Food & Beverage$34,847 (3.1%)
Research$18,347 (1.6%)
Education$374.53 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $747,576 | 247 | 66.1% |
| Consulting Fee | $189,218 | 57 | 16.7% |
| Travel and Lodging | $137,355 | 316 | 12.2% |
| Food and Beverage | $34,847 | 1,064 | 3.1% |
| Unspecified | $18,347 | 9 | 1.6% |
| Honoraria | $2,600 | 3 | 0.2% |
| Education | $374.53 | 17 | 0.0% |
Payments by Type
General
$1.1M
1,704 transactions
Research
$18,347
5 transactions
Ownership
$0
4 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| ABBVIE INC. | $740,236 | 910 | $0 (2024) |
| Takeda Pharmaceuticals U.S.A., Inc. | $101,941 | 147 | $0 (2024) |
| PFIZER INC. | $95,404 | 137 | $0 (2024) |
| Lilly USA, LLC | $55,055 | 61 | $0 (2024) |
| Janssen Scientific Affairs, LLC | $28,634 | 33 | $0 (2023) |
| Janssen Biotech, Inc. | $27,349 | 115 | $0 (2024) |
| Eli Lilly and Company | $26,362 | 15 | $0 (2024) |
| Celltrion USA Inc. | $19,016 | 24 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $18,570 | 12 | $0 (2022) |
| GastroGPO, LLC | $6,300 | 11 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $152,566 | 308 | ABBVIE INC. ($79,349) |
| 2023 | $139,653 | 303 | AbbVie Inc. ($96,214) |
| 2022 | $130,514 | 226 | ABBVIE INC. ($112,033) |
| 2021 | $140,149 | 161 | AbbVie Inc. ($65,443) |
| 2020 | $127,645 | 129 | AbbVie Inc. ($89,844) |
| 2019 | $166,409 | 209 | AbbVie, Inc. ($88,356) |
| 2018 | $163,439 | 197 | AbbVie, Inc. ($106,447) |
| 2017 | $109,943 | 180 | AbbVie, Inc. ($102,551) |
All Payment Transactions
1,713 individual payment records from CMS Open Payments — Page 1 of 69
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/18/2024 | Celltrion USA Inc. | VEGZELMA (Biological) | Food and Beverage | In-kind items and services | $14.87 | General |
| Category: ONCOLOGY | ||||||
| 12/18/2024 | ABBVIE INC. | SKYRIZI (Biological), RINVOQ | Food and Beverage | In-kind items and services | $9.15 | General |
| Category: IMMUNOLOGY | ||||||
| 12/16/2024 | ABBVIE INC. | RINVOQ (Biological), SKYRIZI | Food and Beverage | In-kind items and services | $17.15 | General |
| Category: IMMUNOLOGY | ||||||
| 12/16/2024 | ABBVIE INC. | RINVOQ (Biological), SKYRIZI | Food and Beverage | In-kind items and services | $2.07 | General |
| Category: IMMUNOLOGY | ||||||
| 12/11/2024 | Daiichi Sankyo Inc. | INJECTAFER (Drug) | Food and Beverage | In-kind items and services | $27.02 | General |
| Category: Iron Deficiency Anemia | ||||||
| 12/11/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $19.85 | General |
| Category: Immunology | ||||||
| 12/10/2024 | ABBVIE INC. | SKYRIZI (Biological) | Food and Beverage | In-kind items and services | $48.47 | General |
| Category: IMMUNOLOGY | ||||||
| 12/10/2024 | Lilly USA, LLC | OMVOH (Drug) | Food and Beverage | In-kind items and services | $22.20 | General |
| Category: Immunology | ||||||
| 12/09/2024 | ABBVIE INC. | — | Food and Beverage | In-kind items and services | $107.95 | General |
| 12/07/2024 | Janssen Biotech, Inc. | TREMFYA (Drug), STELARA | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,500.00 | General |
| Category: Immunology | ||||||
| 12/05/2024 | Madrigal Pharmaceuticals | RESMETIROM (Drug) | Food and Beverage | In-kind items and services | $40.52 | General |
| Category: LIVER DISEASE | ||||||
| 12/04/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $23.34 | General |
| Category: Immunology | ||||||
| 12/03/2024 | Ardelyx, Inc. | IBSRELA (Drug) | Food and Beverage | In-kind items and services | $19.98 | General |
| Category: GASTROENTEROLOGY | ||||||
| 12/02/2024 | ABBVIE INC. | SKYRIZI (Biological) | Food and Beverage | In-kind items and services | $9.96 | General |
| Category: IMMUNOLOGY | ||||||
| 12/02/2024 | ABBVIE INC. | RINVOQ (Biological), SKYRIZI | Food and Beverage | In-kind items and services | $6.01 | General |
| Category: IMMUNOLOGY | ||||||
| 11/27/2024 | ABBVIE INC. | SKYRIZI (Biological), RINVOQ | Food and Beverage | In-kind items and services | $11.43 | General |
| Category: IMMUNOLOGY | ||||||
| 11/27/2024 | ABBVIE INC. | RINVOQ (Biological), SKYRIZI | Food and Beverage | In-kind items and services | $3.10 | General |
| Category: IMMUNOLOGY | ||||||
| 11/26/2024 | PFIZER INC. | XELJANZ (Drug), VELSIPITY | Food and Beverage | In-kind items and services | $15.27 | General |
| Category: GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | ||||||
| 11/26/2024 | ABBVIE INC. | RINVOQ (Biological), SKYRIZI | Food and Beverage | In-kind items and services | $7.74 | General |
| Category: IMMUNOLOGY | ||||||
| 11/25/2024 | Madrigal Pharmaceuticals | RESMETIROM (Drug) | Food and Beverage | In-kind items and services | $21.54 | General |
| Category: LIVER DISEASE | ||||||
| 11/20/2024 | ABBVIE INC. | RINVOQ (Biological), SKYRIZI | Food and Beverage | In-kind items and services | $9.88 | General |
| Category: IMMUNOLOGY | ||||||
| 11/18/2024 | PFIZER INC. | XELJANZ (Drug), VELSIPITY | Food and Beverage | In-kind items and services | $4.05 | General |
| Category: GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | ||||||
| 11/14/2024 | Celltrion USA Inc. | ZYMFENTRA (Biological) | Consulting Fee | Cash or cash equivalent | $3,990.00 | General |
| Category: GASTROENTEROLOGY | ||||||
| 11/14/2024 | Celltrion USA Inc. | ZYMFENTRA (Biological) | Travel and Lodging | In-kind items and services | $204.21 | General |
| Category: GASTROENTEROLOGY | ||||||
| 11/14/2024 | Celltrion USA Inc. | ZYMFENTRA (Biological) | Education | In-kind items and services | $150.00 | General |
| Category: GASTROENTEROLOGY | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL-ARM, PLACEBO-CONTROLLED MAINTENANCE STUDY OF MIRIKIZUMAB IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS (LUCENT 2) | Eli Lilly and Company | $17,508 | 1 |
| A PHASE 3, MULTICENTER, OPEN-LABEL EXTENSION STUDY TO EVALUATE THE LONG TERM EFFICACY AND SAFETY OF MIRIKIZUMAB IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS LUCENT 3 | Eli Lilly and Company | $822.02 | 3 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 2 | 36 | 55 | $17,732 | $4,887 |
| 2022 | 4 | 76 | 288 | $52,519 | $14,287 |
| 2021 | 6 | 143 | 189 | $80,006 | $21,032 |
| 2020 | 9 | 205 | 280 | $115,653 | $26,731 |
Total Patients
460
Total Services
812
Medicare Billing
$66,937
Procedure Codes
22
All Medicare Procedures & Services
22 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 24 | 43 | $7,568 | $3,063 | 40.5% |
| 45380 | Biopsy of large bowel using a flexible endoscope | Facility | 2023 | 12 | 12 | $10,164 | $1,824 | 17.9% |
| 99439 | Chronic care management services for two or more chronic conditions, additional 20 minutes of clinical staff time directed by health care professional, per calendar month | Office | 2022 | 15 | 140 | $21,280 | $4,678 | 22.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 29 | 51 | $8,840 | $3,702 | 41.9% |
| 99490 | Chronic care management services, first 20 minutes of clinical staff time directed by health care professional, per calendar month | Office | 2022 | 16 | 80 | $8,000 | $3,398 | 42.5% |
| 45380 | Biopsy of large bowel using a flexible endoscope | Facility | 2022 | 16 | 17 | $14,399 | $2,508 | 17.4% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 51 | 74 | $14,441 | $6,762 | 46.8% |
| 45385 | Removal of polyps or growths in large bowel using an endoscope (colonoscopy) using a mechanical snare | Facility | 2021 | 19 | 19 | $20,273 | $3,850 | 19.0% |
| 96413 | Infusion of chemotherapy into a vein up to 1 hour | Office | 2021 | 13 | 31 | $17,453 | $3,113 | 17.8% |
| 45380 | Biopsy of the large bowel using an endoscope (colonoscopy) | Facility | 2021 | 19 | 19 | $16,093 | $2,739 | 17.0% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Office | 2021 | 16 | 16 | $5,241 | $1,843 | 35.2% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 13 | 18 | $3,024 | $1,435 | 47.5% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2021 | 12 | 12 | $3,481 | $1,290 | 37.1% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 72 | 118 | $23,749 | $8,872 | 37.4% |
| 45385 | Removal of polyps or growths of large bowel using an endoscope | Facility | 2020 | 20 | 20 | $21,340 | $4,182 | 19.6% |
| 96413 | Infusion of chemotherapy into a vein up to 1 hour | Office | 2020 | 16 | 40 | $22,520 | $3,980 | 17.7% |
| G0105 | Colorectal cancer screening; colonoscopy on individual at high risk | Facility | 2020 | 12 | 12 | $9,336 | $2,267 | 24.3% |
| 45380 | Biopsy of large bowel using an endoscope | Facility | 2020 | 18 | 18 | $15,338 | $2,043 | 13.3% |
| 99204 | New patient office or other outpatient visit, typically 45 minutes | Office | 2020 | 17 | 17 | $5,573 | $1,667 | 29.9% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2020 | 15 | 15 | $4,518 | $1,404 | 31.1% |
| 43239 | Biopsy of the esophagus, stomach, and/or upper small bowel using an endoscope | Facility | 2020 | 16 | 17 | $9,962 | $1,242 | 12.5% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 19 | 23 | $3,317 | $1,075 | 32.4% |
About Dr. Jonathon Chapman, MD
Dr. Jonathon Chapman, MD is a Internal Medicine healthcare provider based in Baton Rouge, Louisiana. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 08/24/2007. The National Provider Identifier (NPI) number assigned to this provider is 1689867434.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Jonathon Chapman, MD has received a total of $1.1M in payments from pharmaceutical and medical device companies, with $152,566 received in 2024. These payments were reported across 1,713 transactions from 48 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($747,576).
As a Medicare-enrolled provider, Chapman has provided services to 460 Medicare beneficiaries, totaling 812 services with total Medicare billing of $66,937. Data is available for 4 years (2020–2023), covering 22 distinct procedure/service records.
Ad
Practice Information
- Specialty Internal Medicine
- Other Specialties Gastroenterology
- Location Baton Rouge, LA
- Active Since 08/24/2007
- Last Updated 11/09/2014
- Taxonomy Code 207R00000X
- Entity Type Individual
- NPI Number 1689867434
Products in Payments
- SKYRIZI (Biological) $193,694
- Humira (Biological) $177,790
- HUMIRA (Biological) $123,562
- XELJANZ (Drug) $87,232
- RINVOQ (Biological) $73,249
- Entyvio (Biological) $66,291
- STELARA (Biological) $43,254
- ENTYVIO (Biological) $34,229
- OMVOH (Drug) $30,603
- ZEPOSIA (Drug) $19,245
- ZYMFENTRA (Biological) $18,930
- TREMFYA (Drug) $12,385
- PillCam (Device) $3,204
- EUCRISA (Drug) $630.00
- INJECTAFER (Drug) $495.15
- GI GENIUS (Device) $333.80
- REMICADE (Biological) $326.13
- VELSIPITY (Drug) $301.25
- Ozanimod (Drug) $239.43
- XIFAXAN (Drug) $174.42
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Internal Medicine Doctors in Baton Rouge
Dr. Donna Ryan, M.d, M.D
Internal Medicine — Payments: $1.1M
Internal Medicine $1.1M
Mr. Gerald Calegan, Md, MD
Internal Medicine — Payments: $485,303
Internal Medicine $485,303
Abdulla Majid-Moosa, D.o, D.O
Internal Medicine — Payments: $133,349
Internal Medicine $133,349
Dr. Sean Shannon, M.d, M.D
Internal Medicine — Payments: $132,839
Internal Medicine $132,839
Dr. Randall Beyl, Md, MD
Internal Medicine — Payments: $120,599
Internal Medicine $120,599
Andrew Dalovisio, M.d, M.D
Internal Medicine — Payments: $105,923
Internal Medicine $105,923